Identification of breast cancer prognosis markers using Integrative sparse Boosting

Methods of Information in Medicine

Volumn 51, Issue 2, 2012, Pages 152-161

  Ma, S ^a   Huang, J ^b   Xie, Y ^c   Yi, N ^d  

^a YALE UNIVERSITY   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Breast cancer prognosis; Gene expression; Integrative analysis; Sparse boosting

Indexed keywords

TUMOR MARKER;

ARTICLE; BREAST TUMOR; EVALUATION; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; MICROARRAY ANALYSIS; MONTE CARLO METHOD; PATHOLOGY; PROGNOSIS; STATISTICAL MODEL; STATISTICS;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MICROARRAY ANALYSIS; MODELS, STATISTICAL; MONTE CARLO METHOD; PROGNOSIS; STATISTICS AS TOPIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84863338220     PISSN: 00261270     EISSN: None     Source Type: Journal    
DOI: 10.3414/ME11-02-0019     Document Type: Article

References (36)

1. Cheang M, van de Rijin M, Nielson TO. Gene expression profiling of breast cancer. Annual Review of Pathology: Mechanisms of Disease 2008; 3: 67-97.
2. Knudsen S. Cancer Diagnostics with DNA Microarrays. Wiley; 2006.
3. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. JNCI 2006; 98: 262-272.
4. van't Veer LJ, Dai H, Vijver MJ van de, He YD, Hart AA, Mao M, Peterse HL, Kooy K van der, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
5. Huang Y, Huang J, Shia BC, Ma S. Identification of cancer genomic markers via integrative sparse boosting. Biostatistics 2011. In press.
6. Ma S, Huang J, Wei F, Xie Y, Fang K. Integrative analysis of multiple cancer prognosis studies with gene expression measurements. Statistics in Medicine 2011. In press.
7. Ma S, Huang J, Song X. Integrative analysis and variable selection with multiple high-dimensional datasets. Biostatistics 2011. In press.
8. Guerra R. Goldstein DR. Meta-Analysis and Combining Information in Genetics and Genomics. Chapman and Hall/CRC; 2009.
9. Wei LJ. The accelerated failure time model: a useful alternative to the Cox regression model in survival analysis. Statistics in Medicine 1992; 11: 1871-1879.
10. Schmid M, Hothorn T. Flexible boosting of accelerated failure time models. BMC Bioinformatics 2008; 9: 269.
11. Wang Z, Wang CY. Buckley-James boosting for survival analysis with high dimensional biomarker data. Statistical Applications in Genetics and Molecular Biology 2010; 9 (1): 24.
12. Datta S, Le-Rademacher J, Datta S. Predicting patient survival from microarray data by accelerated failure time modeling using partial least squares and LASSO. Biometrics 2007; 63: 259-271.
13. Dettling M. BagBoosting for tumor classification with gene expression data. Bioinformatics 2004; 20: 3583-3593.
14. Dettling M, Buhlmann P. Boosting for tumor classification with gene expression data. Bioinformatics 2003; 19: 1061-1069.
15. Buhlmann P, Hothorn T. Boosting algorithms: regularization, prediction and model fitting (with discussion). Stat Sci 2007; 22: 477-505.
16. Buhlmann P, Yu B. Sparse boosting. Journal of Machine Learning Research 2006; 7: 1001-1024.
17. Rhodes D, Chinnaiyan AM. Bioinformatics strategies for translating genome-wide expression analyses into clinically useful cancer markers. Annals of the New York Academy of Sciences 2004; 1020: 32-40.
18. Rhodes D, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. Large-scale meta-analysis of cancer microarray data identified common transcriptional profiles of neoplastic transformation and progression. PNAS 2004; 101: 9309-9314.
19. Stute W. Consistent estimation under random censorship when covariables are available. Journal of Multivariate Analysis 1993; 45: 89-103.
20. Berk RA. Statistical Learning from a Regression Perspective. Springer; 2008.
21. Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning. Springer; 2009.
22. Friedman JH. Greedy function approximation: a gradient boosting machine. Annals of Statistics 2001; 29: 1189-1232.
23. Zhang J, Ramadge PJ. Sparse boosting. 2009 International Conference on Acoustics, Speech and Signal Processing. 2009.
24. Ma S, Huang J, Shi M, Li Y, Shia BC. Semipara - metric prognosis models in genomic studies. Briefings in Bioinformatics 2010; 11: 385-393.
25. Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF, Bild A, Iversen ES, Liao M, Chen CM, West M, Nevins JR, Huang AT. Gene expression predictors of breast cancer outcomes. Lancet 2003; 361: 1590-1596.
26. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Rijn M van de, Jefble frey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 2001; 98: 10869-10874.
27. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET. Breast cancer classification and prognosis based on gene expression profiles from a population based study. PNAS 2003; 100: 10393-10398.
28. Gu F, Schumacher FR, Canzian F, Allen NE et al. Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer. Cancer Epidemiology, Biomarkers, Prevention 2010; 19: 2877-2887.
29. He C, Kraft P, Chasman DI, Buring JE et al. A largescale candidate gene association study of age at menarche and age at natural menopause. Human Genetics 2010; 128: 515-527.
30. Turashvili G, Bouchal J, Baumforth K, Wei W, et al. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 2007; 7: 55.
31. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Research 2009; 69: 4116-4124.
32. Creighton CJ, Massarweh S, Huang S, Tsimelzon A, et al. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Research 2008; 68: 7493-7501.
33. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, et al. Gene expression profiling and histopathological characterization of triple-negative/basallike breast carcinomas. Breast Cancer Research 2007; 9: R65.
34. Kulasingam V, Diamandis EP. Proteomics analysis of conditioned media from three breast cancer cell lines: a mine for biomarkers and therapeutic targets. Mol Cell Proteomics 2007; 6: 1997-2011.
35. Emery LA, Tripathi A, King C, Kavanah M, et al. Early dysregulation of cell adhesion and extracellular matrix pathways in breast cancer progression. Am J Pathol 2009; 175: 1292-1302.
36. Poola I, DeWitty RL, Marshalleck JJ, Bhatnagar R, et al. Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis. Nat Med 2005; 11: 481-483.